Baylor College of Medicine: Folic Acid Reduces Risk of Defects Linked to Dolutegravir
July 24, 2019
July 24, 2019
HOUSTON, Texas, July 24 [TNSmedicalresearch] -- The Baylor College of Medicine issued the following news release:
Dolutegravir is a preferred medication for treating HIV infection, but it recently has been linked to a 6- to 9-fold increase in the risk for neural tube defects among babies born to mothers receiving the drug during early gestation. Researchers at Baylor College of Medicine suspected that folic acid (vitamin B9), which is known to prevent the vast majority of neural tub . . .
Dolutegravir is a preferred medication for treating HIV infection, but it recently has been linked to a 6- to 9-fold increase in the risk for neural tube defects among babies born to mothers receiving the drug during early gestation. Researchers at Baylor College of Medicine suspected that folic acid (vitamin B9), which is known to prevent the vast majority of neural tub . . .